Correlations Of CYP2C19 Gene Polymorphism With Platelet Inhibitionrate And Clopidogrel Low Responsiveness

ObjectiveTo retrospectively analyze the relationships of CYP2C19 genotype polymorphism with platelet inhibition rate and clopidogrel low responsiveness in patients undergoing PCI during perioperative administration of clopidogrel,then providing more evidence-based evidence for the precise administration in patients taking clopidogrel during the perioperative period.MethodsA total of 404 patients who took clopidogrel after PCI were selected from February 2016 to February 2017 in the Department of Cardiology,the First Affiliated Hospital of Zhengzhou University.Blood tests for CYP2C19 genotype and platelet inhibition rate on the third day after PCI.All patients were divided into three groups,based on the CYP2C19 genotype.Platelet inhibition rate,which induced by ADP and residual platelet function,were examined by thrombelastogram,clopidogrel low responsiveness(CLR)group was defined as platelet inhibition rate of < 30%.Through statistical analysis,the relationship between CYP2C19 genotype and platelet inhibition rate and clopidogrel hyporesponsiveness was evaluated among the three groups.Results1.Among the 404 patients,the proportions of fast metabolizing,moderate metabolizing,and slow metabolizing CYP2C19 genotypes were 45.5%,45.3%,and 9.2%,respectively.2.There was no statistically significant difference in general data(including age,sex,platelet,hypertension,diabetes mellitus,hyperlipidemia)between the fast,moderate,and slow metabolic groups(P>0.05).3.The mean platelet inhibitory rates of fast,intermediate and slow metabolizer groups were 79.3%,81.3%,61.1%,respectively.There was no statistically significant difference in the platelet inhibition rate between the three groups(P =0.312).4.There was no statistically significant difference in the clopidogrel low responsiveness between the three groups(P = 0.295).ConclusionThere is no correlation of CYP2C19 genotype with platelet inhibition rate and clopidogrel low responsiveness in patients taking clopidogrel in perioperative period of PCI.The clopidogrel inhibition of platelet aggregation can’t fully reflect only by testing the CYP2C19 genotype.